Search Videos and More
Dana-Farber Researcher Awarded Victoria Mock New Investigator Award
Rachel Pozzar, PhD, RN, a nurse scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, has been awarded the 2023 Oncology Nursing Society’s (ONS) Victoria Mock New Investigator Award.Dana-Farber Research Publication 02.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic Leukemia
On Thursday, January 19, 2023, the FDA approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).Study Links Key Activating Enzymes to Specific Sites on Proteins in Cells
Thousands of proteins in a human cell are regulated by phosphorylation -- the addition of small chemical groups to the proteins’ amino acids by enzymes called protein kinases.More Than 120 Dana-Farber Affiliated Faculty Named as 2023 Top Doctors in Boston Magazine
Boston magazine has named more than 120 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide.Immunotherapy With Two Novel Drugs Shows Activity in Colorectal Cancer
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.Molecular Tumor Board Provides Useful Assist in Cancer Precision Medicine
The field of precision cancer medicine has become so complex that even experienced oncologists can find it challenging to decipher the results of molecular tests of tumor tissue and navigate treatment options for patients. At Dana-Farber Cancer Institute, a multi-disciplinary team has been assisting gastrointestinal cancer physicians – reviewing test results and offering timely recommendations on treatment options.Study Finds Racial Inequities in Access to Opioids Among Older Patients With Cancer Near End of Life
Older Black and Hispanic patients with advanced cancer are less likely to receive opioid medications for pain relief in the last weeks of life than White patients, a new study led by Dana-Farber Cancer Institute investigators found.Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows
A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.New Receptor “Decoy” Drug Neutralizes COVID-19 Virus and Its Variants
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant.Research With a Worldwide Reach
Around the world, Dana-Farber's Susan F. Smith Center for Women's Cancers is known not just for its exceptional patient care, but also for the driving force its physician-scientists play in developing new paradigms of cancer treatment through pioneering research and clinical trials.Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists
As patients with cancer increasingly receive treatment in community hospitals and clinics and many such centers experience a shortage of oncologists, a group of physicians at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School has proposed the first-ever training blueprint for oncologists planning careers in a community or academic-community setting.